Drug Profile
Research programme: placental-derived stem cell therapeutics - UniQuest
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator University of Queensland
- Developer UniQuest; University of Queensland
- Class Anti-ischaemics; Stem cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ischaemia; Wounds
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Ischaemia in Australia (Parenteral)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Wounds in Australia (Parenteral)
- 04 Aug 2016 Research programme: placental-derived stem cell therapeutics - UniQuest is available for licensing - http://uniquest.com.au/filething/get/15962/Regenerative%20medicine%20portfolio.pdf